Out-of-pocket costs and oral cancer medication discontinuation in the elderly

Journal of Managed Care Pharmacy

Volumn 20, Issue 7, 2014, Pages 669-675

  Kaisaeng, Nantana ^a   Harpe, Spencer E ^c   Carroll, Norman V ^b  

^a The Food and Drug Administration Thailand Ministry of Public Health   (Thailand)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ERLOTINIB; IMATINIB; LETROZOLE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; MELPHALAN; PREDNISOLONE;

AGED; ARTICLE; CANCER PATIENT; DRUG COST; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MOUTH CANCER; PRESCRIPTION; THERAPY DELAY; COST; CROSS-SECTIONAL STUDY; ECONOMICS; MEDICATION COMPLIANCE; MOUTH NEOPLASMS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY; BREAST CANCER; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; GERIATRIC PATIENT; HIGH RISK PATIENT; LOGISTIC REGRESSION ANALYSIS; MAINTENANCE THERAPY; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; STATISTICAL ANALYSIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COST SHARING; CROSS-SECTIONAL STUDIES; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HUMANS; LOGISTIC MODELS; MALE; MEDICARE PART D; MEDICATION ADHERENCE; MOUTH NEOPLASMS; UNITED STATES;

EID: 84903152096     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.7.669     Document Type: Article

References (49)

1. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61(6):1-50. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf. Accessed May 8 2014.
2. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2009. National Cancer Institute. April 2012. Bethesda, MD, based on November 2011 SEER data submission. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/browse_csr.php?section=2&page=sect_02_table.21. html. Accessed May 12, 2014.
3. National Cancer Institute. The cost of cancer. 2011. Available at: http://www.cancer.gov/aboutnci/servingpeople/understanding-burden/costofcancer. Accessed May 23, 2014.
4. Reese DW, Skyberg JT, Kuntz GA. Oral oncology treatment regimens and the role of medication therapy management on patient adherence and compliance. 2009. Available at: http://accc-cancer.org/publications/pdf/usoncologywhitepaper. pdf. Accessed May 12, 2014.
5. Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(Suppl 3):S1-S14.
6. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm. 2008;14(6):553-60. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=7948.
7. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638-45.
8. Castaldi PJ, Rogers WH, Safran DG, Wilson IB. Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease. Chest. 2010;138(3):614-20.
9. Conwell LJ, Esposito D, Colby M, et al. Promising therapies, prohibitive costs: a qualitative assessment of the effects of the Medicare Part D doughnut hole on access to costly cancer medications. Community Oncol. 2011;8(3):111-17.
10. American Cancer Society. Cancer treatment and survivorship: facts & figures 2012-2013. Atlanta, GA: American Cancer Society; 2012. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-033876.pdf. Accessed May 12, 2014.
11. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120-28.
12. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602-06.
13. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549-55.
14. O'Sullivan J. Medicare Part D prescription drug benefit: a primer. Congressional Research Service Report for Congress. 2008. Available at: http://amcp.org/WorkArea/DownloadAsset.aspx?id=11060.
15. Barnes L, Burich M, Little A, Nowak M, Haroldson B. Oral oncolytics: addressing the barriers to access and identifying areas for engagement. February 2010. Available at: http://www.communityoncology.org/pdfs/avalerecoa- oral-oncolytics-study-summary-report.pdf. Accessed May 12, 2014.
16. Nekhlyudov L, Madden J, Graves AJ, et al. Cost-related medication nonadherence and cost-saving strategies used by elderly Medicare cancer survivors. J Cancer Surviv. 2011;5(4):395-404.
17. Castaldi PJ, Rogers WH, Safran DG, Wilson IB. Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease. Chest. 2010;138(3):614-20.
18. Melloni C, Alexander KP, Ou FS, et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol. 2009;104(2):175-81.
19. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient outof- pocket payments matter? Arthritis Rheum. 2008;59(10):1519-26.
20. Garavalia L, Garavalia B, Spertus JA, Decker C. Exploring patients' reasons for discontinuance of heart medications. J Cardiovasc Nurs. 2009;24(5):371-79.
21. Daugherty KK, Butler JS, Mattingly M, Ryan M. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc (2003). 2005;45(3):371-75.
22. Piette JD, Heisler M, Horne R, Alexander, GC. A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures. Soc Sci Med. 2006;62(4):846-57.
23. Zivin K, Ratliff S, Heisler MM, Langa KM, Piette JD. Factors influencing cost-related nonadherence to medication in older adults: a conceptually based approach. Value Health. 2010;13(4):338-45.
24. Research Data Assistance Center (RESDAC). Medicare data documentation. Available at: http://www.resdac.org/ddvh/index.asp. Accessed May 12, 2014.
25. Research Triangle Institute (RTI). RTI spatial impact factor datadownload- data. Available at: https://rtispatialdata.rti.org/Download/Data/tabid/56/Default.aspx. Accessed May 12, 2014.
26. Bureau of Labor Statistics. Consumer Price Index research series using current methods (CPI-U-RS). Available at: http://www.bls.gov/cpi/cpiursai1978_ 2010.pdf. Accessed May 12, 2014.
27. Lamb E. Top 200 drugs of 2008. Pharmacy Times. May 15, 2009. Available at: http://www.pharmacytimes.com/publications/issue/2009/2009- 05/RxFocusTop200Drugs-0509. Accessed May 12, 2014.
28. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. Version 2. 2011. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed May 12, 2014.
29. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic myelogeneous leukemia. Version 2. 2012. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed May 12, 2014.
30. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. Version 2. 2012. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed May 12, 2014.
31. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. Version 1. 2013. Available at: http://www. nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed May 12, 2014.
32. Chronic Conditions Data Warehouse. Chronic condition categories. Centers for Medicare & Medicaid Services. Available at: http://www.ccwdata. org/chronic-conditions/index.htm. Accessed May 12, 2014.
33. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008;49(3):446-54.
34. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25(6):481-96.
35. Egede LE, Gebregziabher M, Dismuke CE, et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012;35(12):2533-39.
36. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-99.
37. Center for Medicare & Medicaid Services. Information pharmacists can use on: closing the coverage gap. Revised May 2013. Available at: http://www.cms.gov/Outreach-and-Education/Outreach/Partnerships/Downloads/11522-P.pdf. Accessed May 12, 2014.
38. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89(7):826-31.
39. Prince HM, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma. 2007;48(1):46-55.
40. Offidani M, Leoni P, Bringhen S, et al. Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a casematch study. Leuk Lymphoma. 2010;51(8):1444-49.
41. Zamagni E, Petrucci A, Tosi P, et al. Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. Ann Hematol. 2012;91(3):419-26.
42. van Rhee F, Dhodapkar M, Shaughnessy JD Jr, et al. First thalidomide clinical trial in multiple myeloma: a decade. Blood. 2008;112(4):1035-38.
43. Kelly K, Azzoli CG, Zatloukal P, et al. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. J Thorac Oncol. 2012;7(6):1041-48.
44. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005;11(18):6414-21.
45. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-88.
46. Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86(6):471-74.
47. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117 (14):3733-36.
48. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556-62.
49. Danilak M, Chambers CR. Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract. 2013;19(2):105-10.